检索结果 - Cristina Ivanescu

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial

    Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical tr... 由 D. Cella, Cristina Ivanescu, Stefan Holmström, Cat N. Bui, James Spalding, Karim Fizazi

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials

    Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials 由 Fred Saad, Cristina Ivanescu, D. Phung, Yohann Loriot, Sarang Abhyankar, Tomasz M. Beer, Bertrand Tombal, Stefan Holmström

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

    Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, pha... 由 Bertrand Tombal, Fred Saad, David F. Penson, Maha Hussain, Cora N. Sternberg, Robert Morlock, Krishnan Ramaswamy, Cristina Ivanescu, Gerhardt Attard

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

    Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, rando... 由 David Cella, Robert J. Motzer, Cristina Suárez, Steven I. Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel Wallace, Burçin Şimşek, Joshua Zhang, Cristina Ivanescu, Andrea B. Apolo, Toni K. Choueiri

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

    Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial 由 David Cella, Viktor Grünwald, Bernard Escudier, Hans J. Hammers, Saby George, Paul Nathan, Marc‐Oliver Grimm, Brian I. Rini, Justin Doan, Cristina Ivanescu, Jean Paty, Sabeen Mekan, Robert J. Motzer

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES... 由 Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi, B. Yа. Alekseev, Taro Iguchi, Russell Z. Szmulewitz, Thomas W. Flaig, Bertrand Tombal, Robert Morlock, Cristina Ivanescu, Krishnan Ramaswamy, Fred Saad, Andrew J. Armstrong

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9

    783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/G... 由 Ana Oaknin, Bradley J. Monk, Ignace Vergote, Andréia Cristina de Melo, Y.M. Kim, Alla Lisyanskaya, Vanessa Samouëlian, H.S. Kim, E.A. Gotovkin, Fernanda Damian, Chang Cl, Shunji Takahashi, J. Li, Melissa Mathias, Matthew G. Fury, Cristina Ivanescu, Matthew Reaney, James Harnett, Chun‐I Chen, Krishnansu S. Tewari

    出版 2021
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

    Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial 由 Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, O. N. Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Hârza, М. И. Коган, B. Yа. Alekseev, Cora N. Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Thomas E. Hutson

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer

    EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer 由 Ana Oaknin, Bradley J. Monk, Ignace Vergote, Andréia Cristina de Melo, Yong‐Man Kim, Alla S. Lisyanskaya, Vanessa Samouëlian, Hee Seung Kim, Evgeniy A. Gotovkin, Fernanda Damian, Chih‐Long Chang, Shunji Takahashi, Jingjin Li, Melissa Mathias, Matthew G. Fury, Cristina Ivanescu, Matthew Reaney, Patrick R. LaFontaine, Israel Lowy, James Harnett, Chieh-I Chen, Krishnansu S. Tewari

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: